Figure 8.

Follistatin shows reduced secretion from the preeclamptic placenta but is reversed by Rosiglitazone. Secretion of Follistatin (FST) was measured via Luminex assay from conditioned media from non-treated control and preeclamptic (PE) placentas (A) and vehicle- or Rosiglitazone (Rosi)-treated PE placentas (B). FST secretion was significantly reduced in the PE placenta compared to control placentas (A, n > 10) however, Rosi treatment led to a significantly increased secretion of FST from the PE placenta compared to vehicle-treated PE placentas (B, n = 14). (Protein secretion was measured by a Luminex assay where experimental values were determined relative to a standard curve. Statistical analysis was performed by student’s t-test to determine significant differences between groups, * p < 0.05, bar plots and data reported are reported as mean pg/mL values ± SEM).